Ceria nanoparticles for the treatment of Parkinson-like diseases induced by chronic manganese intoxication
- 12 February 2015
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (26) , 20432-20439
Abstract
Ceria nanoparticles with controlled size have been studied as antioxidant agents for the in vitro protection of catecholaminergic cells (PC12) exposed to manganese, which is responsible for an occupational form of Parkinson-like disease.Keywords
This publication has 29 references indexed in Scilit:
- The hallmarks of Parkinson's diseaseThe FEBS Journal, 2013
- Epigallocatechin gallate attenuates L-DOPA-induced apoptosis in rat PC12 cellsNutrition Research and Practice, 2013
- Pharmacological potential of cerium oxide nanoparticlesNanoscale, 2011
- Metal Emissions and Urban Incident Parkinson Disease: A Community Health Study of Medicare Beneficiaries by Using Geographic Information SystemsAmerican Journal of Epidemiology, 2010
- Manganese and its Role in Parkinson’s Disease: From Transport to NeuropathologyNeuroMolecular Medicine, 2009
- Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neuronsBiomaterials, 2007
- Nanosized CeO2–SiO2, CeO2–TiO2, and CeO2–ZrO2 Mixed Oxides: Influence of Supporting Oxide on Thermal Stability and Oxygen Storage Properties of CeriaCatalysis Surveys from Asia, 2005
- Electron Localization Determines Defect Formation on Ceria SubstratesScience, 2005
- Enhancing Effect of Manganese on L‐DOPA‐Induced Apoptosis in PC12 CellsJournal of Neurochemistry, 1999
- l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its AutoxidationJournal of Neurochemistry, 1995